Matt Petoe is an Associate Professor at the Florey Institute of Neuroscience and Mental Health, specialising in movement disorders research. His research experience focuses on the design and execution of human clinical studies in sensory neuroscience, therapeutic neuromodulation, and implantable medical devices.
Matt holds a PhD in biomedical engineering (University of Queensland, 2010). His postdoctoral training was supported by the Stroke Foundation at Auckland City Hospital, New Zealand, where he used MRI and transcranial magnetic stimulation to study motor recovery after stroke. Subsequent roles include device development and visual rehabilitation for bionic eye recipients at the Bionics Institute (2012-2023) and industry-based clinical research at Deep Brain Stimulation Technologies Pty Ltd.
The Australian Epilepsy Project has seven MRI scanning sites across five states as part of a national network to provide epilepsy patients with access to advanced diagnostic testing that was otherwise
15 October 2025
The Florey has reported on an MRI-guided focused ultrasound (MRgFUS) rapidly becoming a treatment of choice for essential tremor. Florey imaging experts work alongside Austin Health specialists workin
08 July 2025
Reported by 9News, Clinical Director of The Florey Professor Graeme Jackson was interviewed about the technology developed at the Australian Epilepsy project.
26 June 2025
Donanemab, developed by Lilly, is the first disease-modifying treatment for early-stage Alzheimer’s disease to be approved for use in Australia. The National Imaging Facility supported its developme
16 June 2025